Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429
Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD
Company to hold conference call at 8:30 a.m. EDT today
The Company will host a conference call and live audio webcast on Wednesday, September 20, 2023 at 8:30 a.m. Eastern Daylight Time. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international). To access the telephone replay of the call, dial (877) 344-7529 (domestic) or (412) 317-0088 (international), passcode ID 6807709. The webcast and telephone replay will be archived on the Company's website at www.regulusrx.com following the call.
https://finance.yahoo.com/news/regulus-therapeutics-announces-positive-topline-110000484.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.